NC
BMRN icon

Nexthera Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nexthera Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-341,400
Closed -$29.1M – 25
2018
Q4 		$29.1M Buy
341,400
+41,400
+14% +$3.94M 11.98% 2
2018
Q3 		$29.1M Hold
300,000
– – 5.57% 5
2018
Q2 		$28.3M Buy
300,000
+192,300
+179% +$16.8M 4.38% 5
2018
Q1 		$8.73M Buy
107,700
+4,100
+4% +$352K 1.44% 23
2017
Q4 		$9.24M Buy
+103,600
New +$9.01M 1.7% 18

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Nexthera Capital's BMRN Position: Q2 2019 in Review

Nexthera Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 8,250 shares — an estimated $733K sold.

Nexthera Capital first reported a position in BMRN in Q2 2017 and held it in 5 quarters. The position peaked at $21M in Q1 2018. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

  • Nexthera Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Nexthera Capital sold 8,250 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $733K.
  • Nexthera Capital first reported a position in BioMarin Pharmaceuticals in Q2 2017 and held it in 5 quarters.
  • Nexthera Capital's BioMarin Pharmaceuticals position peaked at $21M in Q1 2018.
  • 482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.